• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Striking the Right Balance for Eligibility Criteria for Clinical Trials in Inflammatory Bowel Disease.

作者信息

Solitano Virginia, Jairath Vipul, Danese Silvio

机构信息

Department of Medicine, Division of Gastroenterology, Western University, London, Canada.

Departments of Medicine, Epidemiology and Biostatistics, Western University, London, Canada.

出版信息

United European Gastroenterol J. 2025 May;13(4):512-514. doi: 10.1002/ueg2.12749. Epub 2025 Jan 6.

DOI:10.1002/ueg2.12749
PMID:39757894
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12090820/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a96a/12090820/c3f53edc0be2/UEG2-13-512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a96a/12090820/c3f53edc0be2/UEG2-13-512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a96a/12090820/c3f53edc0be2/UEG2-13-512-g001.jpg

相似文献

1
Editorial: Striking the Right Balance for Eligibility Criteria for Clinical Trials in Inflammatory Bowel Disease.社论：为炎症性肠病临床试验的入选标准找到恰当平衡
United European Gastroenterol J. 2025 May;13(4):512-514. doi: 10.1002/ueg2.12749. Epub 2025 Jan 6.
2
Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis.炎症性肠病临床试验中入选标准的演变：一项临床试验数据库分析
United European Gastroenterol J. 2025 May;13(4):542-551. doi: 10.1002/ueg2.12731. Epub 2024 Dec 19.
3
Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.随机 II 期和 III 期辅助和新辅助乳腺癌试验的纳入标准：不是入组的显著障碍。
Clin Trials. 2012 Oct;9(5):652-9. doi: 10.1177/1740774512456453.
4
Is Irritable Bowel Syndrome Considered in Clinical Trials on Physical Therapy Applied to Patients with Temporo-Mandibular Disorders? A Scoping Review.针对颞下颌关节紊乱症患者的物理治疗临床试验中是否考虑了肠易激综合征？一项范围综述。
Int J Environ Res Public Health. 2020 Nov 17;17(22):8533. doi: 10.3390/ijerph17228533.
5
Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer's Disease Trials.利用真实世界数据优化临床试验入选标准设计：以阿尔茨海默病试验为例。
AMIA Annu Symp Proc. 2021 Jan 25;2020:717-726. eCollection 2020.
6
Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials.完善肌萎缩侧索硬化症临床试验的纳入标准。
Neurology. 2019 Jan 28;92(5):e451-e460. doi: 10.1212/WNL.0000000000006855.
7
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials.关于扩大炎症性肠病临床试验资格标准的建议。
J Crohns Colitis. 2024 Jun 22. doi: 10.1093/ecco-jcc/jjae097.
8
A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group.
J Clin Epidemiol. 1998 Feb;51(2):69-79. doi: 10.1016/s0895-4356(97)00240-0.
9
A review of research on eligibility criteria for clinical trials.临床试验入选标准研究述评。
Clin Exp Med. 2023 Oct;23(6):1867-1879. doi: 10.1007/s10238-022-00975-1. Epub 2023 Jan 5.
10
Is Irritable Bowel Syndrome Considered as Comorbidity in Clinical Trials of Physical Therapy Interventions in Fibromyalgia? A Scoping Review.在纤维肌痛物理治疗干预的临床试验中，肠易激综合征是否被视为合并症？一项范围综述。
J Clin Med. 2021 Oct 18;10(20):4776. doi: 10.3390/jcm10204776.

本文引用的文献

1
The Future of Clinical Trials in Inflammatory Bowel Disease.炎症性肠病临床试验的未来
Clin Gastroenterol Hepatol. 2025 Feb;23(3):480-489. doi: 10.1016/j.cgh.2024.06.036. Epub 2024 Jul 16.
2
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials.关于扩大炎症性肠病临床试验资格标准的建议。
J Crohns Colitis. 2024 Jun 22. doi: 10.1093/ecco-jcc/jjae097.
3
Toward Patient Centricity: Why Do Patients With Inflammatory Bowel Disease Participate in Pharmaceutical Clinical Trials? A Mixed-Methods Exploration of Study Participants.
迈向以患者为中心：炎症性肠病患者为何参与药物临床试验？对研究参与者的混合方法探索。
Crohns Colitis 360. 2024 Mar 15;6(2):otae019. doi: 10.1093/crocol/otae019. eCollection 2024 Apr.
4
Patients With Crohn's Disease and Permanent Ileostomy Are Universally Excluded From Clinical Trials: A Systematic Review.患有克罗恩病和永久性回肠造口术的患者普遍被排除在临床试验之外：系统评价。
Am J Gastroenterol. 2023 Jul 1;118(7):1285-1288. doi: 10.14309/ajg.0000000000002215. Epub 2023 Feb 8.
5
Is it time to include older adults in inflammatory bowel disease trials? A call for action.是否到了将老年人纳入炎症性肠病临床试验的时候了？呼吁采取行动。
Lancet Healthy Longev. 2022 May;3(5):e356-e366. doi: 10.1016/S2666-7568(22)00060-5. Epub 2022 May 4.
6
Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials.溃疡性结肠炎药物研发临床试验中少数族裔代表性不足及种族报告缺失
Inflamm Bowel Dis. 2022 Aug 1;28(8):1293-1295. doi: 10.1093/ibd/izab362.
7
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.扩大入选标准以使临床试验更具代表性：美国临床肿瘤学会与癌症研究之友联合研究声明
J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.
8
Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review.发表于高影响力综合医学期刊的随机对照试验的纳入标准：一项系统抽样综述
JAMA. 2007 Mar 21;297(11):1233-40. doi: 10.1001/jama.297.11.1233.